Skip to content

Pulmonary Rehabilitation in Asthmatic Patient

Pulmonary Rehabilitation in Asthmatic Pediatric Patients: Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02383069
Enrollment
66
Registered
2015-03-09
Start date
2015-02-28
Completion date
2018-08-31
Last updated
2019-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthmatic, Children

Keywords

Pulmonary rehabilitation, Asthma, Children, Teenager, Physical capacity

Brief summary

Asthma is one of the main chronic diseases in childhood and it is characterized by the inflammation of airways. Individuals with chronic lung disease are more susceptible to present reduction in exercise tolerance due to pulmonary limitations. The pulmonary rehabilitation may improve the physical capacity in asthmatic patients, as observed in other chronic lung diseases.

Detailed description

The asthmatic patient's clinical changes may impair their functional capacity and exercise tolerance. Thus, the treatment of these individuals should be extended to pulmonary rehabilitation. Randomized clinical trials have shown interesting results, whether in cardiopulmonary conditions, quality of life or in the number of crises, after applying pulmonary rehabilitation program in asthmatic children and adolescents. In a systematic review on physical training with asthmatic children and adolescents the authors concluded that physical activity should be recommended to this population, although some issues have not yet been clarified due to limitations in the clinical trial. The control of the disease has not been evaluated by specific questionnaires in any study. The assessment of inflammatory markers was rarely addressed and the same occurred in the quality of life after physical training. In addition, it is possible to question the intensity and frequency of training, factors that can significantly contribute to the intervention results. All these information let us know that is necessary a randomized control trial to answer questions about physical characteristics, quality of life, inflammatory markers, and muscles strength.

Interventions

OTHERIntervention Group

Aerobic training

OTHERControl Group

Chest physiotherapy: Flutter and muscle stretching

Sponsors

University of Nove de Julho
CollaboratorOTHER
Fundação de Amparo à Pesquisa do Estado de São Paulo
CollaboratorOTHER_GOV
Federal University of Minas Gerais
CollaboratorOTHER
Fernanda de Cordoba Lanza
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* between six and 18 years old * asthma-diagnosed patients * under medical treatment and disease control

Exclusion criteria

* fail to carry out the protocol evaluations * interrupt the medical care and/or drug-based treatment * acute lung infection or other chronic lung diseases * other comorbidities (neuropathies, heart disease) * missing in more than 20% the rehabilitation protocol

Design outcomes

Primary

MeasureTime frameDescription
Physical capacity as measure by distance walked of shuttle walk test and oxygen consumption (VO2)Physiscal capacity will be measured at the beginning and at the end of the protocol (after 8 weeks)Modified shuttle test was conducted

Secondary

MeasureTime frameDescription
Muscle strength as measure by electromyography (EMG)Muscles strenght will be measured at the begening and at the end of the protocol (after 8 weeks).1 maximal repetition was performed
Muscle endurance as measure by electromyography (EMG)Muscles endurance will be measured at the begening and at the end of the protocol (after 8 weeks).
Quality of life measured by Pediatric questionnaireQuesitionnaire will be measured at the begening and at the end of the protocol (after 8 weeks).
Inflammatory markers as measure by interleukinesInflamatory markers will be measured at the begening and at the end of the protocol (after 8 weeks).

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026